Entospletinib

Entospletinib
Clinical data
Other names	GS-9973
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine;
CAS Number	1229208-44-9;
PubChem CID	59473233;
DrugBank	12121;
UNII	6I3O3W6O3B;
KEGG	D11209;
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6;

Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk).[1] It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).[2]

References

"Definition of entospletinib". NCI Cancer Dictionary. National Cancer Institute.
"Entospletinib - Gilead Sciences". Adis Insight.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.